FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553573182> ?p ?o ?g. }

• W2553573182 abstract "Abstract Leukemia stem cells (LSCs), and especially quiescent LSCs, have a dual role as tumor initiating and therapy-refractory cells. Therefore, even if anti-tumor treatment clears a disease burden consisting mostly of proliferating leukemia progenitor cells (LPCs), it usually fails to eradicate therapy-refractory LSCs and also therapy-resistant LPCs. LSCs, including quiescent LSCs and LPCs accumulate high numbers of spontaneous and drug-induced DNA lesions, including highly lethal DNA double-strand breaks (DSBs). Thus, LSCs and/or LPCs may be “addicted” to particular DNA repair mechanisms and targeting these pathways could sensitize LSCs to the lethal effect of unrepaired DSBs. DSBs are usually repaired by two major mechanisms, homologous recombination repair (HRR) and non-homologous end-joining (NHEJ). While NHEJ plays a major role in quiescent cells, HRR works predominantly on broken replication forks in proliferating cells. Normal quiescent cells employ DNA-PK (PRKDC, XRCC5, XRCC6, LIG4) –mediated NHEJ to repair DSBs whereas PARP1-dependent NHEJ serves as back-up. Normal proliferating cells use PARP1-mediated base excision repair (BER) to prevent DSBs at collapsed replication forks, whereas BRCA (BRCA1, BRCA2, PALB2, RAD51 paralogs, RAD51)-mediated HRR serves as back-up to repair stalled/broken forks. The existence of these pathways creates the opportunity to apply “synthetic lethality” triggered by PARP1 inhibitors (PARP1i) in DNA-PK –deficient therapy-refractory quiescent LSCs and BRCA-deficient therapy-resistant proliferating LSCs/LPCs. This hypothesis is supported by PARP1i-mediated synthetic lethality in BRCA1-/- proliferating and XRCC6-/-quiescent cells. Since inactivating mutations in BRCA and DNA-PK pathways are rather rare in leukemias we hypothesize that Gene Expression and Mutation Analysis (GEMA) can identify individual patients with leukemias displaying “spontaneous” and oncogene-induced downregulation of DSB repair genes which will be sensitive to “synthetic lethality” triggered by PARP1i +/- already approved drugs. GENE EXPRESSION ANALYSIS: Global mRNA microarrays and qRT-PCR followed by immunofluorescent protein staining identified primary AMLs and ALLs from individual patients displaying BRCA- and/or DNA-PK –deficient phenotype (downregulation of at least one member of BRCA and/or DNA-PK pathway). Quiescent DNA-PK –deficient LSCs and proliferating BRCA-deficient LSCs/LPCs, but not DNA-PK and BRCA –proficient counterparts were sensitive to olaparib and BMN673 +/- already approved drugs. GENE MUTATION ANALYSIS: BCR-ABL1 downregulates BRCA1 and DNA-PKcs proteins, FLT3(ITD) inhibits BRCA1 protein, and MLL-AF9 and AML1-ETO reduce BRCA2 and XRCC6 proteins, whereas HOXA9+MEIS1 do not affect the expression of DSB repair proteins. These effects were associated with reduced colony formation by BCR-ABL1, MLL-AF9 and AML1-ETO –transformed, but not HOXA9+MEIS1-treasformed Parp1-/-murine bone marrow cells. PARP1i olaparib and BMN673 +/- approved drugs induced DSBs resulting in abrogation of cell proliferation and/or apoptosis in DNA-PK –deficient quiescent LSCs and/or BRCA-deficient proliferating LSCs/LPCs from CML-CP/AP, Ph+ B-ALL, AML and ALL patients. Genetic (Parp1-/-) and pharmacological (olaparib, BMN673) inhibition of PARP1 prolonged survival of mice with CML-CP –like inducible disease and reduced engraftment/prolonged survival of NSG immunodeficient mice with DNA-PK and/or BRCA-deficient primary leukemia (CML-CP, AML and ALL) xenografts in combination with approved drugs. In conclusion, targeting PARP1 resulted in synthetic lethality in quiescent LSCs and/or proliferating LSCs/LPCs from individual patients identified by GEMA, which display specific defects in DSB repair mechanisms. Disclosures Minden: Celgene: Honoraria." @default.
• W2553573182 created "2016-11-30" @default.
• W2553573182 creator A5006306448 @default.
• W2553573182 creator A5006700695 @default.
• W2553573182 creator A5018371071 @default.
• W2553573182 creator A5020022626 @default.
• W2553573182 creator A5023934847 @default.
• W2553573182 creator A5026397928 @default.
• W2553573182 creator A5047214928 @default.
• W2553573182 creator A5049450086 @default.
• W2553573182 creator A5050087793 @default.
• W2553573182 creator A5056367406 @default.
• W2553573182 creator A5057442322 @default.
• W2553573182 creator A5057876965 @default.
• W2553573182 creator A5061196536 @default.
• W2553573182 creator A5063022331 @default.
• W2553573182 creator A5074420457 @default.
• W2553573182 creator A5080315304 @default.
• W2553573182 creator A5084934029 @default.
• W2553573182 date "2014-12-06" @default.
• W2553573182 modified "2023-09-28" @default.
• W2553573182 title "Gene Expression and Mutation Analysis (GEMA) –Guided Precision Medicine Targeting PARP1 to Induce Synthetic Lethality in DNA-PK –Deficient Quiescent and BRCA-Deficient Proliferating Leukemia Stem and Progenitor Cells" @default.
• W2553573182 doi "https://doi.org/10.1182/blood.v124.21.480.480" @default.
• W2553573182 hasPublicationYear "2014" @default.
• W2553573182 type Work @default.
• W2553573182 sameAs 2553573182 @default.
• W2553573182 citedByCount "1" @default.
• W2553573182 countsByYear W25535731822016 @default.
• W2553573182 crossrefType "journal-article" @default.
• W2553573182 hasAuthorship W2553573182A5006306448 @default.
• W2553573182 hasAuthorship W2553573182A5006700695 @default.
• W2553573182 hasAuthorship W2553573182A5018371071 @default.
• W2553573182 hasAuthorship W2553573182A5020022626 @default.
• W2553573182 hasAuthorship W2553573182A5023934847 @default.
• W2553573182 hasAuthorship W2553573182A5026397928 @default.
• W2553573182 hasAuthorship W2553573182A5047214928 @default.
• W2553573182 hasAuthorship W2553573182A5049450086 @default.
• W2553573182 hasAuthorship W2553573182A5050087793 @default.
• W2553573182 hasAuthorship W2553573182A5056367406 @default.
• W2553573182 hasAuthorship W2553573182A5057442322 @default.
• W2553573182 hasAuthorship W2553573182A5057876965 @default.
• W2553573182 hasAuthorship W2553573182A5061196536 @default.
• W2553573182 hasAuthorship W2553573182A5063022331 @default.
• W2553573182 hasAuthorship W2553573182A5074420457 @default.
• W2553573182 hasAuthorship W2553573182A5080315304 @default.
• W2553573182 hasAuthorship W2553573182A5084934029 @default.
• W2553573182 hasConcept C102744134 @default.
• W2553573182 hasConcept C134935766 @default.
• W2553573182 hasConcept C143425029 @default.
• W2553573182 hasConcept C153911025 @default.
• W2553573182 hasConcept C182979987 @default.
• W2553573182 hasConcept C201750760 @default.
• W2553573182 hasConcept C2778480876 @default.
• W2553573182 hasConcept C2778502085 @default.
• W2553573182 hasConcept C2779012473 @default.
• W2553573182 hasConcept C2779962180 @default.
• W2553573182 hasConcept C28328180 @default.
• W2553573182 hasConcept C502942594 @default.
• W2553573182 hasConcept C54355233 @default.
• W2553573182 hasConcept C552990157 @default.
• W2553573182 hasConcept C82381507 @default.
• W2553573182 hasConcept C86803240 @default.
• W2553573182 hasConcept C95444343 @default.
• W2553573182 hasConceptScore W2553573182C102744134 @default.
• W2553573182 hasConceptScore W2553573182C134935766 @default.
• W2553573182 hasConceptScore W2553573182C143425029 @default.
• W2553573182 hasConceptScore W2553573182C153911025 @default.
• W2553573182 hasConceptScore W2553573182C182979987 @default.
• W2553573182 hasConceptScore W2553573182C201750760 @default.
• W2553573182 hasConceptScore W2553573182C2778480876 @default.
• W2553573182 hasConceptScore W2553573182C2778502085 @default.
• W2553573182 hasConceptScore W2553573182C2779012473 @default.
• W2553573182 hasConceptScore W2553573182C2779962180 @default.
• W2553573182 hasConceptScore W2553573182C28328180 @default.
• W2553573182 hasConceptScore W2553573182C502942594 @default.
• W2553573182 hasConceptScore W2553573182C54355233 @default.
• W2553573182 hasConceptScore W2553573182C552990157 @default.
• W2553573182 hasConceptScore W2553573182C82381507 @default.
• W2553573182 hasConceptScore W2553573182C86803240 @default.
• W2553573182 hasConceptScore W2553573182C95444343 @default.
• W2553573182 hasLocation W25535731821 @default.
• W2553573182 hasOpenAccess W2553573182 @default.
• W2553573182 hasPrimaryLocation W25535731821 @default.
• W2553573182 hasRelatedWork W2088568685 @default.
• W2553573182 hasRelatedWork W2093318486 @default.
• W2553573182 hasRelatedWork W2394589397 @default.
• W2553573182 hasRelatedWork W2552713214 @default.
• W2553573182 hasRelatedWork W2563235660 @default.
• W2553573182 hasRelatedWork W2566169584 @default.
• W2553573182 hasRelatedWork W2579276148 @default.
• W2553573182 hasRelatedWork W2584263862 @default.
• W2553573182 hasRelatedWork W2588229608 @default.
• W2553573182 hasRelatedWork W2589022724 @default.
• W2553573182 hasRelatedWork W2594301310 @default.
• W2553573182 hasRelatedWork W2604170775 @default.
• W2553573182 hasRelatedWork W2796207984 @default.
• W2553573182 hasRelatedWork W2807806217 @default.
• W2553573182 hasRelatedWork W2955659134 @default.
• W2553573182 hasRelatedWork W2969121586 @default.
• W2553573182 hasRelatedWork W3061031692 @default.

• next